Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.
You may also be interested in...
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.
Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.